Leveraging a state-of-the-art, purpose-built scientific facility focusing on cancer research, David utilizes quantitative mass spectrometry to identify protein biomarkers as predictors of disease status and response to therapy.
After a PhD and postdoctoral work in pharmacology and toxicology, David shifted the focus of his research to cancer prevention. David established the quantitative mass spectrometry facility in the John van Geest Cancer Research Centre in 2013-2014, ensuring it was well equipped with state-of-the-art technologies to meet the challenge of modern day cancer research.
His current research is directed toward biomarker discovery utilizing biological mass spectrometry to identify protein biomarkers as predictors of disease status and evidence of response to therapy. Primary research areas are prostate cancer, breast cancer, though the techniques can be applied across many conditions. The Research Centre at NTU University (NTU) has active programs of work in the area of head and neck cancer, acute myeloid leukemia, chronic kidney disease and amyotrophic lateral sclerosis among others.
“The John van Geest Cancer Research Centre is a purpose-built scientific facility focusing on cancer research into diagnosis, prognosis and treatment. We aim to save lives and speed recovery by improving the early diagnosis and treatment of cancer, working globally to ensure the benefit is delivered to patients with cancer and to the broader society.”